If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEdx Medical Group Plc Regulatory News (EDX.PL)

EDX Medical Group has transferred from AQUIS to AIM, please follow the AIM page here.

  • There is currently no data for EDX.PL

Director dealing

3 Sep 2025 11:15

RNS Number : 8520X
EDX Medical Group PLC
03 September 2025
 

 

 

3 September 2025

EDX Medical Group plc · EDX

AQSE: EDX

("EDX Medical" or the "Company")

 

Director dealing

 

CAMBRIDGE, UK: EDX Medical Group, plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, today announces that Martin Walton, deputy chairman of the Company, purchased a total of 20,000 ordinary shares in the Company on September 2, 2025, at a price per share of 10.80 pence.

 

Following this purchase, Mr Walton owns 165,714 shares, representing 0.04% of the issued share capital.

 

The directors of the Company accept responsibility for the contents of this announcement.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

MARTIN WALTON

2

Reason for the notification

a)

Position/status

Deputy Chair Board Director

b)

Initial notification/ Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

EDX MEDICAL GROUP PLC

b)

LEI

[213800BZVJZTMCZ6DJ63]

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the finan- cial instrument, type of instrument

Identification code

Ordinary Shares EDX

ISIN GB00BNDMJS47

b)

Nature of the transaction

 

Purchase of shares on market

c)

Price(s) and volume(s)

d)

Aggregated information

- Aggregated volume

Price

single transaction as above

e)

Date of the transaction

2025-09-02

f)

Place of the transaction

AQUIS MARKET

(1) Commission Delegated Regulation (EU) 2016/522 of 17 December 2015 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council as regards an exemption for certain third countries public bodies and central banks, the indicators of market manipulation, the disclosure thresholds, the competent authority for notifications of delays, the permission for trading during closed periods and types of notifiable managers' transactions (see page 1 of this Official Journal).

 

ENDS

 

Contacts:

 

EDX Medical Group plc

Dr Mike Hudson 

(Chief Executive Officer)

 

+44 (0)7812 345 301

 

Oberon Capital

Nick Lovering (Corporate Adviser)

Adam Pollock (Corporate Broking)

Mike Seabrook (Corporate Broking)

 

+44 (0)20 3179 5300

Media House International

Ramsay Smith

 

 

Gary McQueen

+44 (0)7788 414856

ramsay@mediahouse.co.uk

 

+44 (0)7834 694609

gary@mediahouse.co.uk

 

IFC Advisory (Investor Relations)

Tim Metcalfe

Graham Herring

+44 (0) 203 934 6630

 

Notes to Editors:

 

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXSSFFSDEISEFU
12
Date   Source Headline
30th Jun 20262:53 pmRNSTotal Voting Rights
26th Jun 20262:30 pmRNSResults of General Meeting
5th Jun 20267:00 amRNSPosting of Notice of General Meeting
4th Jun 20264:04 pmRNSRule 17 disclosure
4th Jun 20267:00 amRNSExpiration of warrants
13th May 20267:00 amRNSFirst Day of Dealings on AIM
21st Apr 20265:30 pmRNSGranting of options over ordinary shares
13th Apr 20267:00 amRNSProposed application for admission to AIM
1st Apr 20267:00 amRNSTotal Voting Rights
25th Mar 20267:00 amRNSScottish Prostate Cancer Initiative
4th Mar 20264:05 pmRNSExercise of Warrants
27th Feb 20262:55 pmRNSTotal voting rights
27th Feb 20262:52 pmRNSHoldings in Company
27th Feb 20262:49 pmRNSHoldings in Company
27th Feb 20262:48 pmRNSHoldings in Company
16th Feb 20267:00 amRNSEquity Fundraising raises £3.5 million
9th Jan 20267:00 amRNSDirector dealing
8th Jan 20267:00 amRNSDirector dealing
6th Jan 20267:00 amRNSDirector dealing
5th Jan 20267:00 amRNSDirector dealing
2nd Jan 20267:00 amRNSDirector dealing
2nd Jan 20267:00 amRNSDirector dealing
23rd Dec 20257:00 amRNSDirector dealing
23rd Dec 20257:00 amRNSDirector dealing
19th Dec 202512:00 pmRNSInterim report: Six months to 30 September 2025
19th Dec 202512:00 pmRNSInterim report: Six months to 30 September 2025
18th Dec 20257:00 amRNSCommercial launch of bowel cancer testing service
31st Oct 20257:00 amRNSTotal Voting Rights
20th Oct 20257:00 amRNSEDX Medical secures up to £4million funding
7th Oct 202511:33 amRNSAdvance testicular cancer testing service launched
29th Sep 20253:58 pmRNSResult of Annual General Meeting
4th Sep 20257:00 amRNSDirector dealing
3rd Sep 202511:15 amRNSDirector dealing
3rd Sep 20257:00 amRNSDirector dealing
1st Sep 20257:00 amRNSPosting of Notice of AGM and Annual Report
28th Aug 20257:00 amRNSDirector dealing
26th Aug 202510:00 amRNSDirector dealing
22nd Aug 20253:33 pmRNSPublication - Annual Report & Financial Statements
8th Aug 20257:00 amRNSPartnership formed to provide new pneumonia test
3rd Jul 20251:04 pmRNSResult of General Meeting
17th Jun 20257:00 amRNSPosting of notice of General Meeting
16th Jun 20257:00 amRNSMemorandum of Understanding with Spire Healthcare
15th Apr 20257:00 amRNS‘Bed & ISA’ share transfer
11th Apr 20257:00 amRNSNew highly accurate testicular cancer test
3rd Apr 20257:00 amRNSShareholdings update - REPLACEMENT
31st Mar 20257:00 amRNSShareholdings update
20th Mar 20257:00 amRNSEquity Fundraising to raise £3.0 million
6th Mar 202510:00 amRNSService agreement with Royal Marsden NHS Trust
27th Feb 202512:35 pmRNSDirector dealing
25th Feb 20254:11 pmRNSDirector dealing
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.